Association of fibrin and interleukin 8 in human oral squamous cell carcinoma

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 95, Issue 4, 2003, Pages 452-457

  Lalla, Rajesh V ^a   Spiro, Jeffrey D ^a   Tanzer, Marvin L ^a   Kreutzer, Donald L ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; INTERLEUKIN 8; MONOCLONAL ANTIBODY; ANTIBODY; COLORING AGENT; DIAGNOSTIC AGENT; FIBRINOGEN;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUTH CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR CELL; UPREGULATION; CELL CULTURE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; MOUTH TUMOR; PATHOLOGY; ULTRASTRUCTURE;

ANTIBODIES; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; COLORING AGENTS; CYTOPLASM; FIBRIN; FIBRINOGEN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; MOUTH NEOPLASMS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0013173899     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1067/moe.2003.21     Document Type: Article

References (32)

1. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987; 57:673-86.
2. Costantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost 1993; 69:406-14.
3. Lalla RV, Goralnick SJ, Tanzer ML, Kreutzer DL. Fibrin induces IL-8 expression from human oral squamous cell carcinoma cells. Oral Oncol 2001; 37:234-42.
4. Technical Sheet for Anti-Human Fibrinogen (product number F-2506). St. Louis: Sigma Chemical Company; 1998.
5. Cohen RF, Contrino J, Spiro JD, Mann EA, Chen LL, Kreutzer DL. Interleukin-8 expression by head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995; 121:202-9.
6. Bini A, Fenoglio JJ, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin and fibrin(ogen) degradation products in atherosclerosis. Arteriosclerosis 1989; 9:109-21.
7. Technical sheet for mouse anti-fibrin II beta chain antibody (NYB.T2G1). Westbury, NY: Accurate Chemical and Scientific Corp; 1998.
8. Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. Mol Immunol 1984; 21:89-94.
9. Bini A, Mesa-Tejada R, Fenoglio JJ, Kudryk B, Kaplan KL. Immunohistochemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies. Lab Investigation 1989; 60:814-21.
10. Technical sheet for anti-IL-8 antibody (C-19); catalog number sc-1269. Santa Cruz, Calif: Santa Cruz Biotechnology, Inc; 1998.
11. Brown LF, Dvorak AM, Dvorak HF. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis 1989; 140:1104-7.
12. Dvorak HF, Harvey VS, McDonagh J. Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinomas. Cancer Res 1984; 44:3348-54.
13. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2:209-15.
14. Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990; 65:481-5.
15. Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, et al. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990; 10:579-82.
16. Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, et al. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990; 93:516-21.
17. Hoch RC, Schraufstatter IU, Cochrane CG. In vivo, in vitro, and molecular aspects of interleukin-8 and the interleukin-8 receptors. J Lab Clin Med 1996; 128:134-45.
18. Strieter RM, Kunkel SL, Elner VM, Martonyi CL, Koch AE, Polverini PJ, et al. Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol 1992; 141:1279-84.
19. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258:1798-801.
20. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54:3242-7.
21. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151:1105-13.
22. Scheibenbogen C, Mohler T, Haefele J, Hunstein W, Keilholz U. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res 1995; 5:179-81.
23. Eisma RJ, Spiro JD, Kreutzer DL. Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Laryngoscope 1999; 109:687-93.
24. Richards BL, Eisma RJ, Spiro JD, Lindquist RL, Kreutzer DL. Coexpression of interleukin-8 receptors in head and neck squamous cell carcinoma. Am J Surg 1997; 174:507-12.
25. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am J Pathol 1996; 149:247-58.
26. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Jr., Forcier RJ, et al. Rationale and experimental design for the VA Cooperative Study of Anticoagulation (Warfarin) in the Treatment of Cancer. Cancer 1979; 44:732-41.
27. Schlager SI, Dray S. Complete local tumor regression with antibody to fibrin Fragment E. J Immunol 1975; 115:976-81.
28. Zacharski LR, Meehan KR, Algarra SM, Calvo FA. Clinical trials with anticoagulant and antiplatelet therapies. Cancer Metastasis Rev 1992; 11:421-31.
29. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Jr., Forcier RJ, et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 1981; 245:831-5.
30. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med 2000; 342:1953-8.
31. Ghosh M, Aroor AR, Raghavan MR. Clinical utility of serum fibrinogen degradation products (FDP) in the diagnostic and prognostic evaluation of oral cancer. Ann Dent 1990; 49:11-2,45.
32. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999; 5:1369-79.